Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content)
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tdap-IPV (diphtheria and tetanus toxoids adsorbed + acellular pertussis vaccine + inactivated poliovirus vaccine) is a multivalent combination biologic vaccine developed by Sanofi Pasteur. It is formulated as a booster dose for older children, adolescents, and adults who have previously received a primary vaccination series. The vaccine contains adsorbed tetanus toxoid, a reduced dose of diphtheria toxoid, a five-component acellular pertussis preparation (including pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3), and inactivated poliovirus types 1, 2, and 3. It works by inducing active immunity through the production of protective antibodies against *Corynebacterium diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, and poliovirus. Clinical evaluation includes Phase 4 studies assessing long-term safety and immunogenicity when administered alone or concurrently with other vaccines such as the hepatitis B vaccine.
- Brand names
- Adacel-PolioRepevax
- Other names
- Tdap-IPVdTaP-IPVdiphtheria and tetanus toxoids adsorbed + acellular pertussis vaccine + inactivated poliovirus vaccine
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content).